I wanted to get this to you FAST before SpaceX IPOs.
After June 12, most retail investors will be locked out of the real big opportunity.
The banks, funds, and insiders already got in early - before anyone else even had the chance to.
However, there are 5 little known, almost overlooked companies providing the critical infrastructure SpaceX needs.
Goldman Sachs and Morgan Stanley are already secretly loading up on one of these names.
And another is a resource miner that Elon's entire empire (including Tesla) depends on.
No trading guarantees, of course…
But I've detailed all these names (plus a lot more) inside my FREE SpaceX Investing Blackbook.
It's completely FREE today...
So grab it before these names become public knowledge.
Till the next trade,
Lance Ippolito
Can Trupanion Turn Pet Insurance Loyalty Into Real Earnings?
Author: Peter Frank. Publication Date: 6/18/2026.
Key Points
- Trupanion beat Q1 expectations and posted record first-quarter subscription margins, but the stock has continued to struggle.
- Subscriber retention remains a strength, helping support the company’s monthly pet insurance model despite competitive pressure.
- The bull case depends on Trupanion proving that revenue growth and customer loyalty can translate into durable profitability.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
Trupanion (NASDAQ: TRUP) has spent years telling investors a compelling story about pet insurance. Yet despite steadily rising revenue over the years, the company has struggled to translate that growth into profits.
Now, with the company’s first quarter building on positive results from 2025, Trupanion is delivering record margins, an earnings beat, and strong subscriber retention.
BUY THIS: Claim a backdoor stake in SpaceX (Ad)
Marc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade available in your brokerage account today that offers backdoor pre-IPO exposure to SpaceX.
With the IPO date approaching, Chaikin believes this position could benefit from as high as a $122 billion windfall on IPO day - and he warns against buying in on day one due to potential price instability.
See exactly how to make this trade before SpaceX goes publicBut investors seem wary. Growth may not be the issue confronting the company. Compared with other countries, the United States is far behind in pet insurance adoption. Instead, veterinary inflation and industry competition could be the reasons investors remain underwhelmed and may need more patience.
Trupanion Delivers Stronger Financial Results
Trupanion is not typically mentioned when discussing insurers. It does not pay a dividend, and subscription insurance for cats and dogs is a niche that rarely attracts much investor attention. The company is also unusual in the insurance world in that its policies are monthly rather than annual contracts that customers renegotiate each year.
The company’s first-quarter results showed, however, that its model is working. For the first three months of the year, Trupanion reported revenue of $384 million, up 12% from a year earlier and above expectations.
The company’s net income swung from a $1.5 million loss a year ago to a profit of $4.9 million, or 11 cents per share, more than 50% above analysts’ expectations. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rose 42% to $17.4 million.
While the earnings beat was notable, operating margins told a more compelling story. Trupanion’s subscription adjusted operating margin rose to 14.2%, a first-quarter record, up from 12.9%. Adjusted operating income rose 29% year over year to more than $40 million.
Subscriber Loyalty Remains a Strength
Trupanion’s business goes beyond its direct cat-and-dog insurance operations in the United States. The company also operates lower-cost Furkin and PHI Direct brands in Canada, employer programs, and pet health products. Its VetDirect Pay offering allows its insurance coverage to integrate into veterinary claims systems. Over the past few years, the company has also expanded through acquisitions into several countries in Europe, though that remains a small part of its business with only about 64,000 pets covered.
For a company built on monthly subscriptions, that line item is vital and also tells a generally positive story.
Overall, subscription revenue for the quarter rose 16% to $269.5 million, driven by a 5% increase in enrolled subscription pets to 1.1 million. Factoring in all business lines, total pets enrolled declined 2% year over year. Still, monthly average revenue per pet increased to $85.79, compared with $77.53 a year earlier.
This growth is largely sustained by apparent loyalty among subscribers. As of March 31, Trupanion reported monthly retention of 98.35%, meaning fewer than two out of every 100 subscribers canceled.
In all, the company announced in May that it had reached more than $4 billion in total veterinary invoices paid on behalf of policyholders.
Competition and Rising Costs Still Matter
Given the nature of the business, however, investors cannot simply assume a smooth trajectory from here. With its monthly subscription model, the company faces the potential for churn and pricing pressure.
Competition is also increasing in the financial services sector. Traditional insurers, direct-to-consumer startups, and employer-benefit pet insurance programs have all entered or expanded in the category. Nationwide, Lemonade (NYSE: LMND), MetLife (NYSE: MET), and the Healthy Paws unit of Chubb (NYSE: CB) are among the competitors in the segment.
On the positive side, Trupanion’s distribution model relies heavily on recommendations from veterinarians, and that provides some protection. Yet maintaining that advantage requires continued investment in veterinary relationships and brand presence. The cost of acquiring new subscribers is also increasing, rising to $315 in the quarter from $267.
Meanwhile, veterinary costs have climbed sharply over the past decade, driven by advances in veterinary medicine that now include MRI imaging, cancer treatments, orthopedic surgeries, and other procedures that can cost thousands of dollars.
Wall Street Remains Cautiously Optimistic
Analyst sentiment, as well as the company’s stock price, reflects these tensions.
Despite the improved results, shares in the company have fallen by over 35% since the start of the year.
Over the past year, the stock is down more than 50%.
And while two analysts have assigned a Buy rating to the stock, three recommend Hold, and one suggests Sell, indicating just how tentative the outlook remains.
Overall, the company carries a Hold rating.
Even with the Hold rating, the company’s lowest 12-month target price is $31, still well above current trading levels. The average target is $42.25, more than 75% higher.
Growth Potential May Reward Patience
For investors considering Trupanion, patience may be the key. Pet insurance remains dramatically underpenetrated in North America, so there is room to grow. In the United Kingdom and Sweden, for example, pet insurance ownership rates run well into the double digits. In the United States and Canada, the figure is in the low single digits.
The first-quarter results also deserve attention. A record operating margin and a strong earnings beat should not be ignored, along with continued proof that the subscription model generates the kind of customer loyalty that supports long-term economics.
For retail investors who are comfortable owning a company that is still proving its profitability story, TRUP deserves a place on the research list.
That said, this is not a stock for investors who need certainty or income. The company is still working to prove its profitability. The next one or two quarterly reports are likely to be clarifying. The first quarter of 2026 was certainly encouraging. But in Trupanion’s case, the full story continues to be written.
Can D-Wave Hold Its Own Against 2 Fast-Growing Rivals?
Author: Nathan Reiff. Publication Date: 6/16/2026.
Key Points
- D-Wave is a leader in the pure-play quantum computing space, but threats are growing from both smaller and larger companies.
- On the smaller side, an innovative quantum-focused cybersecurity company, Arqit, has plenty of hurdles to overcome but may signal a new face of the industry.
- A larger rival, Qualcomm, is not traditionally thought of as a quantum firm, but its investments in certain quantum companies could play an increasingly important role over time.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
As Q2 2026 wraps up, the quantum computing race is as fierce as ever, and established pure-play companies like D-Wave Quantum Inc. (NYSE: QBTS) are facing new pressures. On one hand, D-Wave must contend with increased activity in the quantum space from larger tech companies like Intel Corp. (NASDAQ: INTC) and IBM Corp. (NYSE: IBM), both of which have made major pushes through new investments or strategic partnerships that leverage their size and operational advantages. This is made more complicated by an infusion of about $2 billion in funding across the industry from the Commerce Department, only a small portion of which is slated to go to D-Wave.
On the other hand, D-Wave also faces often-overlooked threats from smaller, up-and-coming quantum companies. One in particular—Arqit Quantum Inc. (NASDAQ: ARQQ)—may stand out as a new rival in the field. Below, we look at Arqit and a larger company traditionally outside the quantum space, Qualcomm Inc. (NASDAQ: QCOM), that may also threaten D-Wave's status as a leader in the space.
A Highly Speculative Quantum Cybersecurity Play Ahead of Its Time
BUY THIS: Claim a backdoor stake in SpaceX (Ad)
Marc Chaikin, the Wall Street veteran who spotted Nvidia before a 45,000% run, says there's a simple trade available in your brokerage account today that offers backdoor pre-IPO exposure to SpaceX.
With the IPO date approaching, Chaikin believes this position could benefit from as high as a $122 billion windfall on IPO day - and he warns against buying in on day one due to potential price instability.
See exactly how to make this trade before SpaceX goes publicArqit takes a unique approach within the quantum ecosystem in that it is a cybersecurity firm focused on quantum-safe encryption solutions. As quantum computing technology continues to develop, it may introduce new security threats that classical computing systems are not equipped to handle—the risks may even extend to cryptocurrencies. Arqit is now preparing for future security threats with its key distribution architecture.
For the first half of its fiscal 2026 (ending Sept. 30, 2026), revenue soared by about 830% year over year (YOY) on the strength of 11 unique contracts, up from seven a year earlier. The company is making key inroads with telecom network operators, government agencies, defense contractors, and other enterprise organizations, all of which could prove vital as it continues to grow.
By May 20, 2026, Arqit had amassed nearly $36 million in cash. While that remains modest, it is up by about $7 million in less than two months. Supporting Arqit's growth is a collaboration with Intel that sees the former's encryption software pre-installed on select Intel hardware, as well as other partnerships that are emerging.
Investors may be concerned, however, that Arqit has missed some of its sales projections and that the company has diluted shares multiple times in recent years. These are reasons why it carries an overall Hold rating, with one Wall Street analyst suggesting ARQQ is a Buy and another calling it a Sell. Still, the price target of $60 is nearly 230% above current price levels. ARQQ is certainly a speculative and high-risk play, but it represents an early entrant to an industry that could prove transformative—and that may eventually draw investor attention away from firms like D-Wave.
A Non-Quantum Company With an Important Role in Quantum Development
While Arqit has a market capitalization of only around $280 million, Qualcomm is nearly 850 times larger at roughly $238 billion. And though Qualcomm is not a pure-play quantum company—it is a wireless communications and semiconductor firm—it is nonetheless an emerging player in quantum technology through its Qualcomm Ventures arm.
Qualcomm Ventures is a venture capital branch of Qualcomm that invests in quantum computing firms, among others. Notably, Qualcomm Ventures has made a significant investment in control system creator Quantum Machines, the maker of a platform used to control quantum processors.
For Qualcomm, the interest in quantum computing is at least two-fold. For one, the company has significant capital and leverage to participate in the quantum race, despite its traditional focus elsewhere. Beyond that, Qualcomm will benefit from the development of quantum-safe communications hardware. The threat of future quantum-based hacking will no doubt affect the rollout of future 6G networks and beyond, and Qualcomm's products will be safer for customers if the company can play a role in the development of key algorithms and cryptography.
In its latest earnings report, Qualcomm posted a modest 3.5% YOY decline in revenue, even as sales reached $10.6 billion and beat analyst predictions. EPS of $2.65 also beat expectations and came in at the high end of guidance. Some of Qualcomm's non-quantum businesses helped drive performance—including, most notably, its automotive revenue and its data center business. For investors interested in Qualcomm's potential within the quantum space, the buffer provided by this operational diversification may be a strong draw.
This message is a sponsored email from InvestPub, a third-party advertiser of MarketBeat. Why did I get this message?.
If you need assistance with your account, please email MarketBeat's South Dakota based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC.
345 North Reid Place, Sixth Floor, Sioux Falls, S.D. 57103-7078. United States..